Ainos Inc.
AIMD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AIMD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AIMD
Ainos Inc. is a diversified healthcare company focused on point-of-care testing, low-dose interferon alpha therapeutics (VELDONA), and an AI-powered scent digitization platform (AI Nose), with ongoing clinical studies in Taiwan and early-stage commercial activities.
Key risk: Liquidity and going concern
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Ainos Inc..
Ainos Inc. is a diversified healthcare company focused on point-of-care testing, low-dose interferon alpha therapeutics (VELDONA), and an AI-powered scent digitization platform (AI Nose), with ongoing clinical studies in Taiwan and early-stage commercial activities.
- Ainos is developing AI Nose, a proprietary scent digitization platform that converts volatile organic compound signals into machine-readable data using gas sensor arrays and artificial intelligence models [sec_mda · as of 2026-08-03].
- The VELDONA program targets oral warts in HIV-seropositive patients, Sjögren's syndrome, common cold, influenza, and mild COVID-19, with Phase 2 studies completed for most indications and Orphan Drug Designation from the FDA for oral warts in HIV patients [sec_mda · as of 2025-08-13].
- As of June 30, 2026, the company reported cash and equivalents of $1.4M, total revenue of $0.0M, net income of -$4.6M, shareholders' equity of $7.6M, and total debt of $11.0M [sec].
- The company anticipates that cash reserves, business revenues, and potential debt financing will fund operations over the next twelve months, but there is no assurance of profitability [sec_mda · as of 2026-05-13].
- Ainos is expanding AI Nose applications into senior care, hospital infrastructure, emergency care, and exhaled breath analysis, though these remain research- and validation-stage activities [sec_mda · as of 2026-08-03].
What works
- AI Nose platform has potential across industrial, environmental, robotics, and healthcare-adjacent markets, with ongoing validation in hospital and senior care settings [sec_mda · as of 2026-08-03].
- VELDONA has FDA Orphan Drug Designation for oral warts in HIV-seropositive patients, which may provide market exclusivity and development incentives [sec_mda · as of 2025-08-13].
- The company is advancing clinical studies in Taiwan for two lead VELDONA indications (oral warts in HIV patients and Sjögren's syndrome) and for feline chronic gingivostomatitis in veterinary health [sec_mda · as of 2025-08-13].
What to weigh
- The company has no current revenue ($0.0M as of June 30, 2026) and a net loss of $4.6M for the first half of 2026, with an accumulated deficit and reliance on external financing [sec].
- Cash and equivalents of $1.4M as of June 30, 2026, are low relative to total debt of $11.0M, and the company acknowledges uncertainty about raising additional capital if needed [sec_mda · as of 2026-05-13].
- AI Nose applications in healthcare-adjacent settings are still at research- and validation-stage, with no guarantee of commercial adoption or revenue generation [sec_mda · as of 2026-08-03].
- The company has a going concern qualification as of December 31, 2025, with cash of only $417,353 at that time, highlighting liquidity risk [sec_mda · as of 2026-03-30].
From the filings
Quoted directly from source documents.
VELDONA Orphan Drug Designation
“The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for our VELDONA formulation as a potential treatment for oral warts in HIV-seropositive patients.”
SEC MD&A · August 13, 2025
Cash position and going concern
“As of December 31, 2025, the Company had cash and cash equivalents of $417,353.”
SEC MD&A · March 30, 2026
No assurance of profitability
“There can be no assurance that we will be successful in our efforts to make the Company profitable.”
SEC MD&A · May 13, 2026
Risks & what to watch (4)›
Key risks
- Liquidity and going concern — Cash of $1.4M as of June 30, 2026, is insufficient to cover near-term obligations; the company has a going concern qualification and relies on uncertain financing [sec] [sec_mda · as of 2026-03-30].
- No revenue and net losses — Zero revenue and a net loss of $4.6M in the first half of 2026 indicate no path to profitability without significant commercial success or funding [sec].
- Clinical and regulatory uncertainty — VELDONA clinical studies are ongoing in Taiwan; outcomes may not support approval or commercial adoption, and regulatory timelines are uncertain [sec_mda · as of 2025-08-13].
- Early-stage AI Nose commercialization — AI Nose applications in healthcare are still research-stage; commercial adoption and revenue generation are not guaranteed [sec_mda · as of 2026-08-03].
What to watch
- Clinical trial results for VELDONA in oral warts (HIV) and Sjögren's syndrome in Taiwan, which could determine the program's viability [sec_mda · as of 2025-08-13].
- Cash burn rate and any new equity or debt financing announcements, given the low cash position and going concern risk [sec] [sec_mda · as of 2026-03-30].
- Progress in AI Nose validation studies in hospital and senior care settings, which may signal commercial traction [sec_mda · as of 2026-08-03].
- Any partnership or out-licensing deals for VELDONA or AI Nose, which could provide non-dilutive funding [sec_mda · as of 2026-03-30].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Ainos Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Ainos Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
3.4 months
D/E 4.96 · 0% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
10 buys · 6 sells (180d)
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
7
Total value held
$124K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 53,074 | $74K |
| vanguard capital management llc | 18,562 | $26K |
| vanguard fiduciary trust co | 14,169 | $20K |
| blackrock, inc. | 3,065 | $4K |
| citigroup inc | 501 | $696 |
| ubs group ag | 2 | $3 |
| cwm, llc | 1 | $1 |
Short Interest
as of May 20, 2026- % of float
- 0.6%
- Days to cover
- 0.8
- Shares short
- 21,702
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AIMD short interestGovernance
Frequently asked questions
What is the AI investment thesis for Ainos Inc.?
Ainos Inc. is a diversified healthcare company focused on point-of-care testing, low-dose interferon alpha therapeutics (VELDONA), and an AI-powered scent digitization platform (AI Nose), with ongoing clinical studies in Taiwan and early-stage commercial activities.
What is Ainos Inc.'s lead drug candidate?
Ainos Inc.'s most advanced tracked candidate is veldona (Phase 2) for feline chronic gingivostomatitis (FCGS).
Who is the CEO of Ainos Inc.?
Mr. Chun-Hsien Tsai is the chief executive officer of Ainos Inc. (AIMD).
Where is Ainos Inc. headquartered?
Ainos Inc. (AIMD) is headquartered in Houston, TX, United States.
What therapeutic areas does Ainos Inc. focus on?
Ainos Inc. develops therapies across Oncology, Infectious Disease, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.